Synonym
MCI-225; MCI 225; MCI225; DDP-225; DDP 225; DDP225;
IUPAC/Chemical Name
4-(2-Fluorophenyl)-6-methyl-2-piperazin-1-ylthieno[2,3-d]pyrimidine
InChi Key
FVIVKIGLBDRWNR-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H17FN4S/c1-11-10-13-15(12-4-2-3-5-14(12)18)20-17(21-16(13)23-11)22-8-6-19-7-9-22/h2-5,10,19H,6-9H2,1H3
SMILES Code
CC1=CC2=C(C3=CC=CC=C3F)N=C(N4CCNCC4)N=C2S1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
328.40
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Schreiber S, Schreiber F, Lockhart SN, Horng A, Bejanin A, Landau SM, Jagust WJ; Alzheimer’s Disease Neuroimaging Initiative. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology. JAMA Neurol. 2017 Jun 1;74(6):650-659. doi: 10.1001/jamaneurol.2016.5349. PubMed PMID: 28319241; PubMed Central PMCID: PMC5822210.
2: Eguchi J, Inomata Y, Saito K. The anxiolytic-like effect of MCI-225, a selective NA reuptake inhibitor with 5-HT3 receptor antagonism. Pharmacol Biochem Behav. 2001 Apr;68(4):677-83. PubMed PMID: 11526964.
3: Ishigooka J. [Serotonin-noradrenaline reuptake inhibitors(SNRIs)]. Nihon Rinsho. 2001 Aug;59(8):1523-9. Review. Japanese. PubMed PMID: 11519152.
4: Wu YL, Yoshida M, Emoto H, Ishii H, Koga K, Tanaka M. Effects of acute and chronic administration of MCI-225, a new selective noradrenaline reuptake inhibitor with 5-HT3 receptor blocking action, on extracellular noradrenaline levels in the hypothalamus of stressed rats. Jpn J Pharmacol. 2000 May;83(1):31-8. PubMed PMID: 10887938.
5: MCI 225. Drugs R D. 1999 Jul;2(1):51-2. PubMed PMID: 10610283.
6: Eguchi J, Inomata Y, Yuasa T, Egawa M, Saito K. Pharmacological profile of the novel antidepressant 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno-[2,3-d]pyrimidine monohydrate hydrochloride. Arzneimittelforschung. 1997 Dec;47(12):1337-47. PubMed PMID: 9450161.
7: Eguchi J, Saitoh Y, Egawa M, Saito K, Kawamura H. MCI-225, a novel thienopyrimidine analog, enhances attentional eye tracking in midpontine pretrigeminal preparation. Pharmacol Biochem Behav. 1997 Feb;56(2):229-34. PubMed PMID: 9050079.
8: Eguchi J, Iwai K, Yuasa T, Egawa M, Komatsu T, Saito K. Effects of MCI-225 on memory and glucose utilization in basal forebrain-lesioned rats. Pharmacol Biochem Behav. 1995 Aug;51(4):935-9. PubMed PMID: 7675880.
9: Eguchi J, Yuasa T, Egawa M, Tobe A. Effects of a novel compound MCI-225 on impaired learning and memory in rats. Pharmacol Biochem Behav. 1994 Jun;48(2):345-9. PubMed PMID: 8090800.
10: Oishi R, Itoh Y, Adachi N, Saeki K. Effect of a new psychoactive compound, MCI-225, on brain monoamine metabolism in rats. Jpn J Pharmacol. 1993 Oct;63(2):261-4. PubMed PMID: 8283838.
